BPC-157: A Research Overview

Research-use context. This article is an educational summary of the published preclinical literature on BPC-157 for laboratory and research audiences. It is not medical advice, not a dosing guide, and not a recommendation for human use. BPC-157 is not approved by the FDA for human use and is prohibited by WADA, the NFL, the UFC, and the NCAA. All VANTA products are sold strictly for in-vitro and laboratory research use only.

What BPC-157 is

BPC-157 (Body Protection Compound-157) is a synthetic, stable pentadecapeptide — a chain of 15 amino acids — derived from a partial sequence of a protein found in human gastric juice. It was first isolated and characterized by Predrag Sikiric and colleagues at the University of Zagreb, who were investigating why the gastric lining tolerates acid that would damage most other tissues. The fragment they synthesized is unusually stable in gastric acid compared with most peptides, which is one reason it has been studied across so many tissue models.

In its supplied form it is a lyophilized (freeze-dried) powder intended for reconstitution in a controlled laboratory setting.

Proposed mechanism in preclinical models

The recurring theme across the BPC-157 literature is cytoprotection — a broad, tissue-nonspecific protective effect rather than a single receptor target. Mechanistic work has reported several threads:

• Angiogenesis / vascular signaling. Multiple rodent studies associate BPC-157 with promotion of new blood-vessel formation and early revascularization at injury sites, which is often proposed as central to its observed effects.
• Growth-factor and receptor interactions. In isolated rat Achilles tendon fibroblasts, BPC-157 was reported to up-regulate the growth hormone receptor at both mRNA and protein levels in a dose- and time-dependent manner, increasing cell proliferation in the presence of growth hormone.
• Collagen organization. Tendon and ligament models report improved collagen fiber organization and biomechanical strength versus controls.

A 2026 review in Pharmaceuticals summarizing the tendon literature notes that across rodent in-vivo transection/detachment models, BPC-157 “improves functional indices, biomechanical strength, collagen organization, and early revascularization and opposes corticosteroid-induced impairment of tendon healing,” with most studies using systemic intraperitoneal dosing in saline without a carrier.

What the literature does — and does not — establish

This is the part most online write-ups get wrong, and where a research audience needs precision:

• The evidence is overwhelmingly preclinical (animal/in-vitro). A 2025 systematic review in the HSS Journal identified 35 preclinical studies and only one clinical study across all musculoskeletal applications. The picture is built on rodent and cell models, not large human trials.
• Single-group concentration. A large share of the core tendon findings originate from the Sikiric laboratory, with mechanistic contributions from the Chang laboratory in Taiwan. Independent replication of the central findings by unaffiliated groups is still limited.
• Species and translation gap. Rat tendons differ structurally and heal faster than human tendons, and animal dosing (commonly reported around 10 µg/kg or 10 ng/kg intraperitoneally in rodents) does not translate directly to other contexts without pharmacokinetic work that has not been completed.
• Safety in humans is unestablished. Preclinical studies generally report no observed adverse effects, but reviewers explicitly caution that in-human safety remains unknown.

In short: a large, internally consistent preclinical signal, with a correspondingly large gap in high-quality human evidence. That combination is precisely why it remains a research compound.

Where BPC-157 sits in the research landscape

In the preclinical recovery/repair literature, BPC-157 is frequently studied alongside TB-500 (Thymosin Beta-4), with the two sometimes examined in combination in tissue-repair models. It is also discussed in relation to GHK-Cu in the broader context of regenerative and cytoprotective signaling. Researchers comparing these compounds should consult the primary literature for each rather than relying on cross-compound generalizations.

Laboratory handling

BPC-157 is supplied lyophilized. General handling consistent with research-grade peptides:

• Storage (lyophilized): keep cold and protected from light; long-term storage is typically at −20 °C.
• After reconstitution: stored refrigerated (2–8 °C) and used within a limited window per the laboratory’s own protocols.
• Verification: confirm identity and purity against the batch Certificate of Analysis (HPLC purity, mass-spectrometry identity) before use in any protocol.

VANTA supplies BPC-157 as a ≥99% purity research peptide with a batch-specific COA. See our Certificates of Analysis page for how our testing process works.

Frequently asked (research) questions

Is BPC-157 a steroid or a hormone? No. It is a synthetic peptide (15 amino acids) derived from a gastric protein fragment. It is studied for cytoprotective signaling, not as a hormone itself.

Why is it described as “stable”? Relative to many peptides, it resists degradation in gastric acid, which is part of why it has been studied across so many tissue and delivery models in animals.

Is there human clinical evidence? Very little. As of the most recent systematic reviews, the human clinical evidence base is a single study against dozens of preclinical ones.

---

References

1. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006. PubMed: 16583442.
2. Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077. PMC6271067.
3. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. doi:10.1177/15563316251355551.
4. Tendon, Ligament, and Muscle Injury … Stable Gastric Pentadecapeptide BPC 157 — A Review. Pharmaceuticals (MDPI). 2026;19(2):309.

Citations point to the primary preclinical literature. Verify each source and its findings independently; this summary is for research context only and does not describe or recommend human use.